Back to top
more

Haleon PLC Sponsored ADR (HLN)

(Delayed Data from NYSE)

$8.45 USD

8.45
2,892,680

+0.05 (0.60%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.46 +0.01 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

GSK Outperforms Industry on Strength in Key Drugs & Vaccines

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.

Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%

Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.

AHCO vs. HLN: Which Stock Should Value Investors Buy Now?

AHCO vs. HLN: Which Stock Is the Better Value Option?

GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.

HLN vs. ABT: Which Stock Is the Better Value Option?

HLN vs. ABT: Which Stock Is the Better Value Option?

HLN vs. SYK: Which Stock Should Value Investors Buy Now?

HLN vs. SYK: Which Stock Is the Better Value Option?

HLN or SYK: Which Is the Better Value Stock Right Now?

HLN vs. SYK: Which Stock Is the Better Value Option?

HLN or SYK: Which Is the Better Value Stock Right Now?

HLN vs. SYK: Which Stock Is the Better Value Option?

GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.

GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment

GSK's Key Drugs to Drive Sales in a Sluggish Second Half

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).